Small fragments of hyaluronan are increased in individuals with obesity and contribute to low-grade inflammation through TLR-mediated activation of innate immune cells

Mònica Romo1, Cristina López-Vicario1,2, Noelia Perea-Romer3, Mireia Casulleras1,2, Ana Isabel Martínez-Puchol6, Belén Sánchez1,2, Roger Flores-Costa1,2, José Alcaraz-Quiles1, Marta Duran-Güell1,2, Ainitze Ibarzábal5, Juan José Espert5, Joan Clària1,2,4,6,7 and Esther Titos2,4,7✉

© The Author(s) 2022

BACKGROUND AND AIM: Extracellular matrix (ECM) components released during excessive fat mass expansion are considered potential endogenous danger/alarm signals contributing to innate immune system activation. The aim of the current study was to specifically measure plasma levels of low molecular weight (LMW) hyaluronan (HA) and to evaluate its role as pro-inflammatory damage-associated molecular pattern (DAMP) on leukocyte response in the context of human obesity.

SUBJECTS AND METHODS: Participants were selected according to their body mass index (BMI, kg/m²) as non-obese (BMI < 29.9, n = 18) and obese (BMI > 29.9, n = 33). Plasma samples were size-dependent fractionated using ion-exchange chromatography to specifically obtain LMW HA fractions that were subsequently quantified by ELISA. Cell incubation experiments with synthetic HA molecules were performed on freshly Ficoll-isolated neutrophils (PMN) and peripheral blood monocytes (PBMC). Leukocyte and adipose tissue gene expression was assessed by real-time PCR and NF-κB activation by western blot. Plasma cytokine levels were measured by fluorescent bead-based (Luminex) immunoassay.

RESULTS: We observed a statistically significant increase in the circulating levels of HA fragments of LMW in individuals with obesity which were consistent with significant up-regulated expression of the LMW HA synthesizing enzyme hyaluronan synthase-1 (HAS-1) in obese adipose tissue. Gene expression assessment of HA receptors revealed up-regulated levels for TLR2 in both obese PMN and PBMC. Synthetic HA molecules of different sizes were tested on leukocytes from healthy donors. LMW HA fragments (15–40 kDa) and not those from intermediate molecular sizes (75–350 kDa) induced a significant up-regulation of the expression of major pro-inflammatory cytokines such as IL-1β, MCP-1 and IL-8 in PBMC. Importantly, LMW HA was able to induce the phosphorylation of IKK α/β complex supporting its pro-inflammatory role through NF-κB activation.

CONCLUSION: Circulating LMW HA molecules are elevated in obesity and may play an important role in triggering low-grade inflammation and the development of metabolic complications.

International Journal of Obesity; https://doi.org/10.1038/s41366-022-01187-z

INTRODUCTION

During the past decades, studies on tissue dynamics of hyaluronan (HA), the most abundant non-sulfated glycosaminoglycan (GAG) in the extracellular matrix (ECM), have revealed important clues to understand its role in health and disease. Firstly, HA is known to be elevated in several pathological conditions where the structure and organization of the ECM is compromised such as joint disease [1], liver disease [2], obesity and contribute to low-grade inflammation through TLR-mediated activation of innate immune cells [3]. By the direct interaction with specific receptors such as hyaluronan synthase-1 (HAS-1) in obese adipose tissue. Gene expression assessment of HA receptors revealed up-regulated levels for TLR2 in both obese PMN and PBMC. Synthetic HA molecules of different sizes were tested on leukocytes from healthy donors. LMW HA fragments (15–40 kDa) and not those from intermediate molecular sizes (75–350 kDa) induced a significant up-regulation of the expression of major pro-inflammatory cytokines such as IL-1β, MCP-1 and IL-8 in PBMC. Importantly, LMW HA was able to induce the phosphorylation of IKK α/β complex supporting its pro-inflammatory role through NF-κB activation.

CONCLUSION: Circulating LMW HA molecules are elevated in obesity and may play an important role in triggering low-grade inflammation and the development of metabolic complications.

International Journal of Obesity; https://doi.org/10.1038/s41366-022-01187-z

INTRODUCTION

During the past decades, studies on tissue dynamics of hyaluronan (HA), the most abundant non-sulfated glycosaminoglycan (GAG) in the extracellular matrix (ECM), have revealed important clues to understand its role in health and disease. Firstly, HA is known to be elevated in several pathological conditions where the structure and organization of the ECM is compromised such as joint disease [1], liver disease [2], diabetes [3], myocardial damage [4] and certain types of cancers [5]. Measuring its circulatory levels is used as a biomarker to monitor tissue damage [6] and for instance, plasmatic total content of HA is used within different algorithms to predict liver fibrosis [7]. Secondly, distinct functional properties have been ascribed according to its molecular size [8]. Specifically, the presence of HA as a high-molecular-weight (HMW) polymer (>10⁵ kDa) prevents tissue from dehydration and structural compressive damage and has been shown to be anti-inflammatory, anti-angiogenic, and immunosuppressive [9]. In contrast, lower molecular weight (LMW) species (<500 kDa) have been shown to induce the expression of pro-inflammatory cytokines, chemokines, and growth factors and participate in cancer progression [10, 11]. By the direct interaction with specific cell membrane receptors such as its canonic glycoprotein cell adhesion molecule CD44 or the lymphatic vessel endothelial HA receptor-1 (LYVE-1) and indirect interactions with Toll-like receptors (TLR) 2 and 4, HA molecules activate cell signaling cascades and modulate cell

✉Biochemistry and Molecular Genetics Service, Hospital Clinic-IDIBAPS, Barcelona, Spain. 2CIBERehd, Madrid, Spain. 3Gastroenterology Department, Hospital Universitari Mútua de Terrassa, Terrassa, Spain. 4Molecular Biology CORE, Biomedical Diagnostic Center, Hospital Clinic, Barcelona, Spain. 5Gastrointestinal Surgery Department, Hospital Clinic-IDIBAPS, Barcelona, Spain. 6EF-Clíf and Grifols Chair, Barcelona, Spain. 7Department of Biomedical Sciences, University of Barcelona, Barcelona, Spain. ✉email: etitos@clinic.cat

Received: 19 December 2021 Revised: 18 June 2022 Accepted: 4 July 2022
Published online: 27 July 2022
Human leukocytes and the human monocyte cell line THP-1 (ATCC, Manassas, VA, USA) were cultured at a density of 1–2 × 10^5 cells/ml in RPMI 1640 medium containing 10% FBS, L-glutamine and antibiotics at 37°C in a 5% CO_2 incubator. Cell incubations were performed in the presence of either vehicle (0.01% sterile H_2O) or 100 ng/ml LPS (Sigma Aldrich, St Louis, MO, USA) or increasing concentrations of LMW/IMW HA (50, 100, 150 and 200 μg/ml) (R&D Systems Inc., MN, USA) for 6 h in a humidified 5% CO_2 incubator at 37°C. For the assessment of NFκB intracellular signaling, PBMC, and THP1 cells were incubated in the presence of either vehicle (0.01% EtOH) or 10 μM of the proteasome inhibitor MG132 (Merck Millipore, MA, USA) for 30 min before the addition of either LMW HA (100 μg/ml and 100 pg/ml) or 100 ng/ml of the TLR2/6 ligand Pam2CSK4 (InvivoGen, CA, USA) for 2 and 6 h. At the end of the incubation periods, cells were washed and collected for further gene expression analysis. Further details included as Supplementary Information.

**Human Adipose tissue explants and ex vivo incubations**

Human visceral adipose tissue from patients with obesity was collected under sterile conditions. Treatments were performed in DMEM with L-glutamine, antibiotics and 1% endotoxin-free BSA-fatty acid-free (FAF) (Sigma Aldrich, St Louis, MO, USA). Briefly, tissue explants were incubated with vehicle (0.01% EtOH) and the recombinant cytokines IL-1β (25 pg/ml), IL-6 (10 ng/ml) and IL-10 (20 ng/ml) (R&D Systems Inc., MN, USA) for 6 h at 37°C. At the end of the incubation period, tissue explants were frozen at −80°C for further mRNA expression analysis of HAS1. Further details included as Supplementary Information.

**Western blot analysis**

Total protein was separated by SDS-PAGE and transferred onto PVDF membranes by the iBlot Dry Blotting System (Invitrogen, MA, USA). Blots were incubated overnight at 4°C with primary anti-human antibodies for phospho-IKKα/β (2697 S, 1:1000; Cell Signaling Technology, MA, USA), IKKα/β (sc-7607, 1:400; Santa Cruz Biotechnology, TX, USA) phospho-IκBα (sc-746, 1:400; Santa Cruz Biotechnology, TX, USA) and phospho-IκBα (sc-203, 1:200; Santa Cruz Biotechnology). Thereafter, the blots were incubated with either donkey anti-rabbit (Biolegend, CA, USA) or anti-mouse (Cell Signaling Technology) HRP-linked antibody (1:2000). To assess housekeeping protein expression, membranes were rebotted overnight at 4°C with primary rabbit anti-human β-actin HRP conjugate (Cell Signaling Technology). Bands were visualized using the EZ-ECL chemiluminescence detection kit (Biological Industries, Israel). Total IKKα/β, IKK-α and β-actin were used as internal controls when applicable to verify basal level expression and equal protein loading. Further details included as Supplementary Information.

**Luminex xMAP technology**

Cytokine levels were determined in plasma samples using a Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel (Merck Millipore, MA, USA) on a Luminex 100 Bioanalyzer (Merck Millipore). Further details included as Supplementary Information.

**RESULTS**

**Patient characteristics and markers of systemic inflammation**

Individuals included in the study were categorized according to their body mass index (BMI, Kg/m²) in non-obese (CT, BMI < 29.9) and obese (OB, BMI ≥ 29.9) groups. Anthropometric and biochemical parameters collected prior to laparoscopic surgery are shown in Table 1. Elevated plasma levels of C-reactive protein (CRP) and pro-inflammatory cytokines such as IL-6, TNF-α, MCP-1, IL-8, and IL-7 confirmed the existence of an inflammatory state in individuals with...
HA is found to be a size-dependent modulator of in
PMN from OB exhibited up-regulated levels of IL-1
increased numbers of circulating monocytes (Fig.1B) and marked
MCP-1, IL-8, and the anti-inflammatory cytokines IL-1ra and IL-10
fl
flammation we
found a strong correlation between serum glucose levels and total
HA plasma levels in CT and OB individuals. Although we
observed a slight increase in total HA levels was observed
in OB patients presenting fatty liver, no significant statistical
differences were found for neither total nor LMW HA in
comparison with OB patients with an ultrasound image of healthy
liver (Fig. 1F).

Size-dependent inflammatory effects of HA on healthy leukocytes
We next investigated the ability of different size HA molecules to
induce a pro-inflammatory response in PBMC and PMN isolated from
healthy volunteers. As shown in Fig. 2A, PBMC display up-regulated MCP-1 expression in response to LMW HA in a similar extent to those incubated with LPS whereas no changes were observed upon PBMC challenged to IMW HA (Fig. 2A and Supplementary Fig. S2). Dose-dependent experiments on cultured
leukocytes confirmed that LMW HA at concentrations ranging from
50 μg/ml to 200 μg/ml produced a significant stimulatory
effect on cytokine expression in PBMC (Fig. 2B). Of note, freshly
isolated PMN were not responding to LPS either to low or intermediate size HA and only a significant anti-inflammatory
effect was observed for IMW HA in freshly isolated PMN: a finding
that supports opposite roles for HA according to its molecular size
(Fig. 2 and Supplementary Fig. S2).

Obesity modulates the expression of HA receptors in leukocytes and alters their pro-inflammatory response to LMW-HA
The expression of the canonical CD44 receptor and non-canonical TLR2 and TLR4 for HA was next examined on freshly isolated leukocytes from CT and OB individuals. As shown in Fig. 3A, as
compared to CT, OB showed a marked up-regulation of TLR2 mRNA levels in either PBMC and PMN and an opposite gene expression modulation for CD44 between PBMC and PMN being
down-regulated in obese PMB whereas TLR4 did not change. A
deeper analysis on the in vitro response of cultured leukocytes from
CT and OB to a pro-inflammatory dose of LMW HA revealed that
only PBMC from non-obese were able to respond significantly
to LMW HA by increasing the expression of IL-1β, IL-8, and MCP-1.
PBMC from OB remained strongly activated in culture, expressing
higher levels of pro-inflammatory cytokines than CT leukocytes and, importantly, no further additive effects on this pro-
flammatory state were observed upon LMW HA challenge (Fig. 3B, upper panel). Moreover, LMW HA did not change cytokine expression either in CT or OB PMN pointing out blood PBMC as a
cell target for pro-inflammatory effects of LMW HA.

LMW HA upregulates pro-inflammatory markers through NF-kB-dependent signaling in PBMCs and THP-1 monocytes
To explore the intracellular mechanism of LMW HA in leukocyte response, we first assessed whether LMW HA activates canonical NF-kB signaling pathway in the human monocyte-like THP-1 cells. We confirmed that mRNA levels of NF-kB downstream target
genes were significantly up-regulated by LMW HA and the specific
TLR2 agonist, Pam2CSK4 (Fig. 4A) in cell incubations. Of note, gene

| Table 1. Clinical characteristics and anthropometric measurements of the study participants. |
|---------------------------------------------------------------|
| **CT** (n = 18) | **OB** (n = 33) |
| Gender | | |
| Male | 8 | 11 |
| Female | 10 | 22 |
| Age (years) | 46.4 ± 1.7 | 43.0 ± 1.7 |
| BMI (kg/m²) | 19.6 ± 0.5 | 42.6 ± 0.7a |
| Steatosis (%) | – | 18/33 (70%) |
| Glucose (mg/dL) | 87.0 ± 3.2 | 105.5 ± 4.4b |
| Glycated Hemoglobin (%) | – | 5.9 ± 0.1 |
| Triglycerides (mg/dL) | 108 ± 25.3 | 132 ± 12.3 |
| Cholesterol (mg/dL) | 176 ± 7.7 | 188 ± 6.7 |
| ALT (UL/L) | 17.2 ± 3.3 | 31.9 ± 2.8 |
| AST (UL/L) | 32.4 ± 7.1 | 24.2 ± 1.7 |
| Albumin (g/L) | 38.3 ± 1.4 | 42.6 ± 0.5a |
| Platelets (10⁹/L) | 300 ± 29.7 | 288 ± 12.2 |

CT: non-obese individuals (BMI < 29.9), OB: individuals with obesity (BMI > 29.9). Normal reference index: glucose: 65–110 mg/dL, glycated hemoglobin: 4–6%, triglycerides: 50–150 mg/dL, cholesterol: 148–247 mg/dL, albumin: 34–48 g/L, platelets: 150–400 10⁹/L, ALT and AST: 5–40 U/L. Mean ± SEM. BMI: body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase.

α P < 0.0001.  
β P < 0.05 vs. CT.

obesity (Fig. 1A and Table 2). Importantly, a strong positive
association was found between BMI and circulating levels of most
significantly differentiated pro-inflammatory cytokines namely IL-6, 
MCP-1, IL-8, and the anti-inflammatory cytokines IL-1ra and IL-10
(Supplementary Table 2). Systemic inflammation was associated with
increased numbers of circulating monocytes (Fig. 1B) and marked
signs of leukocyte activation as shown in Fig. 1C. Mostly in freshly
isolated PBMC from individuals with obesity which showed
significantly higher expression levels of pro-inflammatory cytokines
(IL-1β, MCP-1, IL-8, and IL-6) as compared to control subjects (Fig. 1C). 
PMN from OB exhibited up-regulated levels of IL-1β with no changes
on MCP-1 and IL-8 when compared to CT.

Increased plasma levels of LMW HA in obese patients
To study the role of circulating HA as a potential self-danger/alarm
signal for leukocyte activation in obesity, we first measured the
total HA plasma levels in CT and OB individuals. Although we
found a strong correlation between serum glucose levels and total
HA levels in plasma (r = 0.54, P < 0.001; n = 35 XY pairs, 
Pearson’s rho test), the total circulatory content of HA was not
significantly different between CT and OB individuals (Fig. 1D). As
HA is found to be a size-dependent modulator of inflammation we
performed a previously described method [23] to specifically
measure plasma content in LMW HA fragments. To test this
methodological approach, we used commercially available
specific-size HA molecules each one containing a polydisperse
mixture of HA fragments with a particular MW average, namely, high
MW HA (HMW HA, 950 KDa), Intermediate MW (IMW HA, 108
KDa) and LMW HA (33 KDa). The specific-size pattern for each
polydisperse HA molecules is shown in Supplementary Fig. S1A. As
shown in Fig. 1E, left panel, the size assessment of each HA
stepwise eluted fraction (lanes 2, 3, 4, and 5) and both total HA
Ladder prior to fractionation (lane 1) and HA resulting from
combined eluted fractions (lane 6) confirmed a precise ion-
exchange column fractionation giving rise in each eluted solutions
a polydisperse smear of HA molecules according to their expected
size pattern. Once we established the procedure, and as
commented before, human plasma samples from CT and OB
individuals were fractionated along with a HA Ladder, and fraction
eluted from 0.425 M NaCl, corresponding to LMW fragments of HA,
was then quantified by ELISA. As shown in Fig. 1E, right panel,
plasma from OB showed significantly higher levels (ng/ml) of LMW 
HA than CT (CT, 7.3 ± 1.2, n = 13 vs OB, 12.0 ± 1.7, n = 30, P < 0.05).
Importantly, among a panel of 19 cytokines, LMW HA levels were
found to be closely associated with both pro-inflammatory 
interleukins IL-8 (r = 0.38, P < 0.05; 42 XY pairs, Spearman’s rho 
test) and IL-7 (r = 0.42, P < 0.01, 42 XY pairs, Spearman’s rho test).
As the presence of important structural liver tissue changes is seen
in people with obesity, we then analyzed HA levels according to
the presence or absence of liver steatosis in individuals with
obesity. Although a slight increase in total HA levels was observed
in OB patients presenting fatty liver, no significant statistical
differences were found for neither total nor LMW HA in
comparison with OB patients with an ultrasound image of healthy
liver (Fig. 1F).
expression levels of TLR2 were found to be also stimulated by LMW HA (Fig. 4B, lower pane). As expected, the addition of the positive control, Pam2CSK4, induced the phosphorylation of IκB kinase (IKKα/β) which later on phosphorylates IκB resulting in its proteasome-mediated degradation and subsequent activation of NF-κB-dependent gene transcription of IL-1β, IL-8, MCP-1 and IL-6 (Fig. 4A, B). The addition of LMW HA showed a similar level of IKKα/β phosphorylation than that observed for Pam2CSK4 but a quick and transient activation IκBα phosphorylation as confirmed upon blockade of proteasome degradation by pre-incubating THP-1 cells with MG132 (Fig. 4B, upper panel). The examination of this pathway on human leukocytes revealed that low...
concentrations of LMW HA as 100 pg/ml were able to activate NF-κB signaling in cultured healthy PBMC, result that supports the role of LMW HA as an inducer of TLR-derived pro-inflammatory response in obesity (Fig. 4C).

**Obese adipose tissue overexpresses hyaluronic acid synthase-1 (HAS-1) and IL-1β induces it expression**

We next investigated the gene expression status of ECM components implicated in HA turnover namely, hyaluronan synthases (HAS1, HAS2, and HAS3) and hyaluronidases (HYAL1, HYAL2, HYAL3) in human adipose tissue from both groups of study (CT and OB). As shown in Fig. 5A, HAS1 was found to be highly overexpressed in adipose tissue from obese patients and no changes were observed for the synthetic enzymes HAS2 and HAS3 or the HA degradative counterparts HYAL1, HYAL2, HYAL3 (Fig. 5B).

Moreover, gene expression of surface receptors involved in HA overexpressed in adipose tissue from obese patients and no (CT and OB). As shown in Fig. 5A, HAS1 was found to be highly components implicated in HA turnover namely, hyaluronan synthases (HAS1, HAS2, and HAS3) and hyaluronidases (HYAL1, HYAL2, HYAL3) in human adipose tissue from both groups of study (CT and OB). As shown in Fig. 5A, HAS1 was found to be highly overexpressed in adipose tissue from obese patients and no changes were observed for the synthetic enzymes HAS2 and HAS3 or the HA degradative counterparts HYAL1, HYAL2, HYAL3 (Fig. 5B).

Moreover, gene expression of surface receptors involved in HA overexpressed in adipose tissue from obese patients and no (CT and OB). As shown in Fig. 5A, HAS1 was found to be highly components implicated in HA turnover namely, hyaluronan synthases (HAS1, HAS2, and HAS3) and hyaluronidases (HYAL1, HYAL2, HYAL3) in human adipose tissue from both groups of study (CT and OB). As shown in Fig. 5A, HAS1 was found to be highly overexpressed in adipose tissue from obese patients and no changes were observed for the synthetic enzymes HAS2 and HAS3 or the HA degradative counterparts HYAL1, HYAL2, HYAL3 (Fig. 5B). Together, these results indicate that adipose tissue as a primary source of LMW HA.

**DISCUSSION**

Increased blood levels of HA have been shown to correlate with metabolic comorbidities associated with obesity namely liver fibrosis raised from non-alcoholic hepatic steatosis [2], atherosclerosis [25], and diabetes [3]. Most of these published data refer to total HA content based on direct quantification of serum levels by conventional enzyme immunoassay which not allows size discrimination of HA extracellular fragments [26]. In the present study, we have adapted a previously described method [23] that uses anion exchange spin columns to size-dependent fractionation of plasma HA content and subsequent measurement of purified LMW HA molecules by conventional HA immunoassay. Importantly, we demonstrated for the first time that patients with obesity show increased circulating levels of LMW HA fragments whereas the total content of plasma HA molecules remains unchanged between control participants and individuals with obesity. This result led us to investigate visceral adipose tissue as the primary source of circulating HA small molecules in obesity. In this regard, and in murine models of inflammation, the accumulation of LMW HA has been ascribed to both the presence of an altered HA enzymatic metabolism [27] and increased non-enzymatic degradation by reactive oxygen species (ROS) which are able to promote tissue HA depolymerization to small fragments [17]. Our results were compatible with the presence of a combination of these two deregulated biological mechanisms occurring simultaneously in obese visceral adipose tissue. Regarding HA metabolic turnover, the statistically significant up-regulation of HAS1 in individuals with obesity with no relevant gene expression changes in HAS2 and HAS3 or HA degrading enzymes was confirmed in our previous microarray public data. Importantly, HAS1 transcript levels were found to be 14.34-fold change up-regulated (P = 0.0024) in obese adipose tissue being the highest altered gene expression observed among all significantly differentially expressed genes between control participants and individuals with obesity (Gene Expression Omnibus under accession number GSE71415). Although published current data are limited, recent studies have emphasized the role of HAS1 in metabolic inflammation as its activity is induced by high glucose levels and cytokines to produce a special type of pericellular hyaluronan coat with pro-inflammatory properties [28, 29]. In this context, pre-clinical studies have demonstrated that the accumulation of HA occurs in muscle from obese mice contributing to the development of insulin resistance and that therapeutic approaches using hyaluronidases or HA synthesis inhibitors show improvements in metabolic outcomes and reduce adipose tissue hypertrophy and inflammation [20, 30]. Our results indicating that HAS1 gene expression could be up-regulated by pro-inflammatory cytokine IL-1β, and that obese patients show both elevated levels of HAS1 mRNA in adipose tissue and plasmatic LMW HA supports the notion that increased hyaluronan synthesis is close-related with the inflammatory state in obesity. Despite this solid evidence, we cannot exclude the non-enzymatic generation of small fragments of HA through ROS-mediated direct cleavage since free oxygen radicals are overproduced during fat mass expansion and could contribute to rising up the LMW HA levels in plasma [17, 31]. A subject that we have not addressed in this study and requires further investigation.

Besides adipose tissue, the liver is another organ usually suffering from ECM disturbances in obese patients and might be also contributing to the plasmatic LMW HA content [32]. Fat accumulation in hepatocytes activates a process of ECM remodeling leading to obese-derived non-alcoholic liver disease newly better defined as metabolic-associated fatty liver disease (MAFLD) [33]. In our study 70% of obese patients showed hepatic steatosis after the ultrasound examination nevertheless, our findings indicated that increased LMW HA levels were independent of the presence or absence of hepatic steatosis pointing to adipose tissue as a primary source of LMW HA.

It is well known that obese visceral adipose tissue plays a major role in the systemic inflammatory state through the unbalance release of the so-called adipokines but also free fatty acids and DAMPs into circulation altering immune homeostasis in individuals with obesity [34]. Our findings confirm a state of systemic low-grade inflammation in obese patients as they presented higher circulating monocyte count and increased plasma levels of classical molecules involved in inflammation namely interleukins, chemokines, the growth factor VEGF, and TNFα. At a cellular level, we found that obesity elicits an activated pro-inflammatory state.
in both freshly isolated PBMC and PMN. This leukocyte behavior has also been observed in previous publications [35] and confirms that blood leukocytes are also contributing to the overall state of chronic low-grade inflammation in individuals with obesity.

Our results on the impact of HA molecules on blood leukocytes, support the general notion that the functional role of HA fragments in the inflammatory response is dependent on their molecular size [32, 36–38]. We confirmed previous findings indicating that small fragments of HA exert pro-inflammatory effects on leukocytes [39, 40]. Specifically, we found that PBMC were particularly reactive to increasing concentrations of LMW HA molecules whereas PMNs remained un-reactive neither to LPS nor LMW HA. Only a significant anti-inflammatory effect was observed when PMN were stimulated with IMW HA a finding that supports described opposite biological actions for HA molecular species of different size [8]. On this subject, the general consensus ascribes anti-inflammatory properties to HMW HA molecules ranging > 10^5 kDa and pro-inflammatory actions to those HA polymers < 500 kDa [10, 11]. Our data regarding this distinct size-dependent effect of molecules < 500 kDa are in line with other published studies that reveal that HA could exert its biological actions through more complex mechanisms than by a mere matter of size. In fact, HA actions depend on factors as the cell type, the pathophysiological context either in fluids or in solid tissues and importantly, the HA receptors involved, their clustering, and their interaction with other cell surface molecules as selectins [11, 26, 41, 42]. The relevant range of concentrations of LMW HA affecting the behavior of blood leukocytes in vivo is

![Fig. 2 Low and Intermediate molecular weight HA effects on cytokine expression in both healthy PBMC and PMN.](image)
another aspect that deserves further investigation. In our in vitro experiments, high doses of LMW HA (50–200 μg/ml) have shown functional relevance while lower doses as 100 pg/ml only have demonstrated NFκB activation without evidence of gene expression changes (data not shown). One of the limitations of our study is that the in vitro model of leukocyte assays is not capturing all the microenvironmental aspects of what is occurring in vivo. Thus, no changes in cytokine gene expression were observed using lower concentrations of LMW HA.

As we have shown, canonical HA receptor (CD44), and TLRs 2 and 4, were found to be expressed by PBMC and PMN in our cohort of individuals. Higher levels of CD44 in obese PMN might be in line with previously published data showing that HA-CD44 interaction is the main mechanism for leukocyte trafficking from the bloodstream into inflamed tissues [43] and PMN recruitment within the hepatic microvasculature in systemic inflammation [44]. In fact, CD44 has found to play a key role in non-alcoholic steatohepatitis development, a hepatic complication of MAFLD.

Fig. 3 Pro-inflammatory effects of LMW HA on healthy and not on obese derived PBMCs in vitro. A TLR2, TLR4, and CD44 mRNA expression in freshly isolated PBMC and PMN from control participants (open bars) and (solid bars) individuals with obesity. B Relative mRNA levels for IL-1β, IL-8, IL-6, and MCP-1 in both healthy human PBMC and PMN incubated for 6 h in the presence of vehicle (sterile water) or LMW HA (100 μg/mL). IL-6 mRNA levels were undetectable in PMN. Data are mean ± SEM n = 3 independent experiments performed in duplicate. *p < 0.05, **p < 0.005, ***p < 0.0005 versus CT subjects or CT-vehicle-treated cells, and a p < 0.05, b p < 0.005 versus CT LMW HA-treated cells.
closely associated to the presence of obesity [45]. Nevertheless, knowing the precise effects of HA fragments on blood leukocyte behavior through their interaction with CD44 are at present unknown and need further studies in the setting of obesity. On the other hand, it has been shown that both TLRs 2 and 4 play crucial roles in the inflammatory response to HA fragments [13, 15, 46]. We have observed that obesity induced a remarkable increase in TLR2 gene expression in both PBMC and PMN while TLR4 mRNA levels remained unchanged. Dasu et al. previously described that TLR2 and TLR4 were increased in monocytes from type 2 diabetic patients and importantly, that HA molecules as well as some of other tissue-damaged associated molecules (HMGB1 and HSP61), co-immunoprecipitated with these receptors and might be linked to their activation through the TLR/NF-κB-dependent pathway [19]. Numerous studies have evidenced that harmful endogenous molecules of non-infectious origin could trigger a state of inflammation by the activation of these innate immune receptors [47]. In agreement with a nice study from Scheibner et al. [46] focused on murine cells, we have demonstrated that LMW HA activate NF-κB-dependent pathway in human PBMC and THP-1 cells thus acting as a danger alarm molecule and suggesting an important role in TLRs activation and

**Fig. 4**  LMW HA upregulates pro-inflammatory markers through NF-κB-dependent signaling in PBMCs and THP-1 monocytes. A Relative mRNA levels for IL-1β, IL-8, MCP-1, and IL-6 in human monocyte-like THP-1 cells incubated for 6 h in the presence of vehicle (sterile water), LMW HA (100 μg/mL), and Toll-like receptor 2 (TLR2) agonist Pam2CSK4 (100 ng/mL). B Upper panel, Representative immunoblots of IKK α/β, pIKK α/β, pIKB α and β-actin in THP-1 cells incubated with vehicle (0.01% ethanol) or MG132 (10 mM) for 30 min before the addition of vehicle (sterile water), Pam2CSK4 (100 ng/mL) or LMW HA (100 μg/mL) (10 ng/mL) for 2 h. Lower panel, relative mRNA levels for TLR2 in human monocyte-like THP-1 cells incubated for 6 h in the presence of vehicle (sterile water), LMW HA (100 μg/mL), and Toll-like receptor 2 (TLR2) agonist Pam2CSK4 (100 ng/mL). Data are mean ± SEM n = 3 independent experiments performed in duplicate. *p < 0.05, ***p < 0.0005 versus vehicle-treated cells. C Representative immunoblots of IKK α/β, pIKK α/β, pIKB α and IKB α in human healthy PBMC incubated with vehicle (0.01% ethanol) or MG132 (10 mM) for 30 min before the addition of vehicle (sterile water), increasing doses of LMW HA (100 pg/mL, and 100 μg/mL), and Pam2CSK4 (100 ng/mL) for 2 h. Results are expressed as mean ± SEM of 3 independent experiments performed in duplicate. *p < 0.05, **p < 0.005, ***p < 0.0005 versus vehicle.
its contribution to low-grade inflammation. Interestingly, LMW HA did not induce a further pro-inflammatory effect on obese leukocytes suggesting that small molecules of HA exert its pro-inflammatory effects early in the progression of obesity.

Summarizing, we demonstrated for the first time that patients with obesity show increased circulating levels of LMW HA fragments in plasma. We also provided additional evidence supporting the role of these small fragments of HA (15–40 kDa) as DAMP molecules in blood leukocytes. Specifically, by inducing the expression of pro-inflammatory genes through TLR/NF-κB signaling in PBMC, LMW HA could be an early contributor to the development of low-grade state of inflammation, the prelude of further metabolic complications associated to obesity.

**DATA AVAILABILITY**

The data that support the findings of this study are available from the corresponding author, ET, upon reasonable request.

**REFERENCES**

1. Sasaki E, Tsuda E, Yamamoto Y, Iwasaki K, Inoue R, Takahashi I, et al. Serum hyaluronan levels increase with the total number of osteoarthritic joints and are strongly associated with the presence of knee and finger osteoarthritis. Int Orthop. 2013;37:925–30.
2. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25:779–86.
3. Morita M, Yano S, Ishibashi Y, Nakata N, Kurioka S, Sugimoto T. Close relationship between serum hyaluronan levels and vascular function in patients with type 2 diabetes. Biomarkers. 2014;19:493–7.
4. Savas G, Kalay N, Altin P, Dursun GK, Cetin M, Aytekin M. Hyaluronan as a promising biomarker for myocardial damage. Tohoku J Exp Med. 2019;248:99–106.
5. Chen IM, Wullemsen N, Dehendorff C, Johansen AZ, Jensen BV, Hansen CP, et al. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Int J Cancer. 2020;146:2913–22.
6. Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49:302–15.
7. Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020;69:1343–52.
8. Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol. 2014;5:101.
9. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–39.
10. Powell JD, Horton MR. Threat matrix: Low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Rev. 2005;201:1–12.
11. Tavianatou AG, Caon I, Franchi M, Pipericikou Z, Galesso D, Karamanos NK. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J. 2019;286:908–918.
12. Yago T, Shao B, Miner JJ, Yao L, Klopocki AG, Maeda K, et al. E-selectin engages PSLG-1 and CD44 through a common signaling pathway to induce integrin α6β1-mediated slow leukocyte rolling. Blood. 2010;116:984–5.
13. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11:1173–7.
14. Kavasi RM, Berdaki A, Spyridaki L, Papoutsidakis A, Corsini E, Tatsakiss A, et al. Contact allergen (PPD and DNCB)-induced keratinocyte sensitization is partly mediated through a low molecular weight hyaluronan (LMWHA)/TLR4/NF-κB signaling axis. Toxicol Appl Pharmacol. 2019;377:114632.
15. Termeer C, Benedix F, Sleeman J, Fiebner C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med. 2002;195:99–111.
16. Siskonen H, Oikari S, Pasonen-Seppänen S, Rilla K. Hyaluronan synthase 1: A mysterious enzyme with unexpected functions. Front Immunol. 2015;6:43.
17. Šoltés L, Mandičič R, Kogan G, Schiller J, Stankovská M, Amhold J. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules. 2006;7:659–68.
18. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.
19. Dassu MR, Devaraj S, Park S, Jialal I. Increased Toll-Like Receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care. 2010;33:861–8.
20. Kang L, Lantier L, Kennedy A, Bonner JS, Mayes WH, Brady DP, et al. Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance. Diabetes. 2013;62:1888–96.
21. Taylor KR, Yamasaki K, De Nardo A, Goodarzi H, Golenbock D, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007;282:18265–75.
22. Bogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, et al. Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulin. Diabetes. 2014;63:2727–43.
23. Yuan H, Amin R, Ye X, De La Motte CA, Cowman MK. Determination of hyaluronan molecular mass distribution in human breast milk. Anal Biochem. 2015;474:78–88.
24. Bhilocha S, Ripal A, Pandya M, Yuan H, Tank M, LoBello J, et al. Agarose and hyaluronan. Anal Biochem. 2017;500-kDa hyaluronan. Anal Biochem. 2011;417:41–9.
25. Fischer JW. Role of hyaluronan in atherosclerosis: Current knowledge and open questions. Matrix Biol. 2019;78–79:324–36.
26. Cowman MK, Lee HG, Schwertfeger KL, McCarthy JB, Turley EA. The content and molecular mass distribution in human breast milk. Anal Biochem. 2013;474:78–88.
27. Lee-Sayer SSM, Dong Y, Arif AA, Olsson M, Brown KL, Johnson P. The where, when, how and why of hyaluronan binding by immune cells. Front Immunol. 2015;6:150.
28. Heldin P, Lin CY, Kollipoulos C, Chen YH, Skandalis SS. Regulation of hyaluronan biosynthesis and clinical impact of excessive hyaluronan production. Matrix Biol. 2019;78–79:100–17.
29. Grandoch M, Flögel U, Virtue S, Maier JK, Jelenik T, Kohlmorgen C, et al. Agaro- and polycacrylamide gel electrophoresis methods for molecular mass analysis of 5- to 500-kDa hyaluronan. Anal Biochem. 2011;417:41–9.
30. Masschelin PM, Chernis N, Hartig SM. The Impact of Oxidative Stress on Adipose Tissue Energy Balance. Front Physiol. 2020;10:1638.
31. Lee BM, Park SJ, Noh I, Kim C-H. The effects of the molecular weights of hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophage. J Appl Physiol. 2020;130:1638.
32. Lee BM, Park SJ, Noh I, Kim C-H. The effects of the molecular weights of hyaluronan on the immune responses. Biostat Mater. 2021:5257.
33. Sokolowska M, Chen LY, Bernal C, Martinez-Anton A, Liu Y, Alsaaity S, et al. Low molecular weight hyaluronan activates cytosolic phospholipase A2a and eicosanoid production in monocytes and macrophages. J Biol Chem. 2014;289:4470–88.
34. Yamawaki H, Hidaka S, Miyoshi T, Takashita K, Ogawa H, Shinochita R, et al. Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology. 2009;19:83–92.
35. Nagy N, Kuipers HF, Marshall PL, Wang E, Kabel G, Bollyky PL. Hyaluronan in immune dysregulation and autoimmune diseases. Matrix Biol. 2019;78–79:292–313.
36. Lu CH, Lin CH, Li KJ, Shen CY, Wu CH, Kuo YM, et al. Intermediate Molecular Mass Hyaluronan and CD44 Receptor Interactions Enhance Neutrophil Phagocytosis and IL-8 Production via p38- and ERK1/2-MAPK Signalling Pathways. Inflammation. 2017;40:1782–93.
37. McKee CM, Penno MB, Cowman M, Burdick MD, Streeter RM, Bao C, et al. Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulin. Diabetes. 2014;63:2727–43.
38. Patouraux S, Rousseau D, Bonnafous S, Lebeau C, Cucci C, Canivet CM, et al. CD44 is a key player in non-alcoholic steatohepatitis. J Hepatol. 2017;67:328–38.
39. Scheibner KA, Lutz MA, Booodo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan Fragments Act as an Endogenous Danger Signal by Engaging TLR2. J Immunol. 2006;177:1272–81.
40. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112.

ACKNOWLEDGEMENTS
We are extremely grateful to both the surgical and nursing staff from the Department of Gastrointestinal Surgery and the Ambulatory Surgery Unit, Hospital Clinic for their implication in providing human samples. The authors also thank Mohamed Kamis for his contributions to this project during his Master Thesis training at our lab.

AUTHOR CONTRIBUTIONS
MR, conducted and analyzed data from patients and cell experiments; CL–V, MC, AI–MF, BS, RF–C, JA–Q, MD–G, contributed to acquisition of data and analysis of in vitro experiments; NP–R, contributed to patients’ recruitment and provided clinical insights; AI and JE contributed to patients’ recruitment; JC contributed to data interpretation and provided feedback. ET designed experiments, conceived, supervised, and wrote the paper.

FUNDING
Supported by Spanish MECD (SAF 15/63674–R) and MCIU (PID2019–105240R–I00), and AGAUR (2017 SGR1449). Generalitat de Catalunya. CIBEREhd is funded by the Institut de Salut Carlos III.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41366-022-01187-z.

Correspondence and requests for materials should be addressed to Esther Titos.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022